Get the Stockscreener App
18.67
4.48%
0.80
After Hours:
18.67
Summit Therapeutics Inc stock is traded at $18.67, with a volume of 1.82M.
It is up +4.48% in the last 24 hours and down -1.74% over the past month.
Summit Therapeutics Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of novel antibiotics for serious infectious diseases. Its CDI (Clostridiodes difficile infection) product candidate is ridinilazole, an orally administered small molecule antibiotic. It has two geographical segments: the United States and the United Kingdom.
See More
Previous Close:
$17.87
Open:
$17.97
24h Volume:
1.82M
Relative Volume:
0.64
Market Cap:
$13.77B
Revenue:
$956.00K
Net Income/Loss:
$-196.68M
P/E Ratio:
-11.11
EPS:
-1.6811
Net Cash Flow:
$-113.02M
1W Performance:
-0.05%
1M Performance:
-1.74%
6M Performance:
+135.44%
1Y Performance:
+687.76%
1-Day Range:
$17.61
$18.90
1-Week Range:
$16.83
$19.18
52-Week Range:
$2.10
$33.89
Summit Therapeutics Inc Stock (SMMT) Company Profile
Name
Summit Therapeutics Inc
Sector
Industry
Phone
305-203-2034
Address
601 BRICKELL KEY DRIVE, MIAMI
Compare SMMT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SMMT
Summit Therapeutics Inc
|
18.67 | 13.77B | 956.00K | -196.68M | -113.02M | -0.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
405.27 | 104.37B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
715.13 | 78.59B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
628.32 | 37.57B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
242.26 | 31.25B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.51 | 27.21B | 3.30B | -501.07M | 1.03B | -2.1146 |
Summit Therapeutics Inc Stock (SMMT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-11-24 | Initiated | Wells Fargo | Overweight |
| Dec-06-24 | Initiated | Jefferies | Buy |
| Nov-04-24 | Initiated | JMP Securities | Mkt Outperform |
| Sep-27-24 | Downgrade | Citigroup | Buy → Neutral |
| Aug-12-24 | Initiated | H.C. Wainwright | Buy |
| May-07-24 | Initiated | Citigroup | Buy |
| Mar-26-24 | Initiated | Stifel | Buy |
| Jun-28-18 | Downgrade | Janney | Buy → Neutral |
| May-02-18 | Initiated | Janney | Buy |
| Apr-12-18 | Reiterated | Needham | Buy |
| Feb-13-18 | Initiated | BTIG Research | Buy |
| Jan-04-18 | Initiated | SunTrust | Buy |
| Dec-01-17 | Resumed | H.C. Wainwright | Buy |
| Nov-16-16 | Reiterated | RBC Capital Mkts | Outperform |
| Oct-05-16 | Reiterated | Needham | Buy |
| Sep-16-16 | Initiated | H.C. Wainwright | Buy |
| Mar-30-15 | Initiated | Needham | Buy |
| Mar-30-15 | Initiated | Oppenheimer | Outperform |
View All
Summit Therapeutics Inc Stock (SMMT) Latest News
10 Best Performing Biotech Stocks in 2024 - Insider Monkey
Is Summit Therapeutics Inc. (SMMT) the Best Performing Biotech Stock in 2024? - Yahoo Finance
Geode Capital Management LLC Increases Holdings in Summit Therapeutics Inc. (NASDAQ:SMMT) - MarketBeat
Barclays PLC Sells 137,195 Shares of Summit Therapeutics Inc. (NASDAQ:SMMT) - MarketBeat
Why Did Summit Therapeutics Inc. (SMMT) Jump Yesterday? - Insider Monkey
Why These 10 Stocks Jumped Yesterday - Insider Monkey
Where Will Summit Therapeutics Be in 5 Years? - Yahoo Finance
3 Stocks That Could Turn $1,000 into $5,000 by 2030 - The Motley Fool
Wellington Management Group LLP Sells 223,964 Shares of Summit Therapeutics Inc. (NASDAQ:SMMT) - MarketBeat
Summit Therapeutics (NASDAQ:SMMT) Trading Up 6.8%Should You Buy? - MarketBeat
(SMMT) Pivots Trading Plans and Risk Controls - Stock Traders Daily
Has Summit Therapeutics Stock Already Peaked? - AOL
State Street Corp Sells 654,623 Shares of Summit Therapeutics Inc. (NASDAQ:SMMT) - MarketBeat
Here's Why Summit Therapeutics Stock Price Rose 6% on Friday - MSN
2 Soaring Stocks That Could Climb 68% to 166% Higher in 2025, According to Wall Street - Yahoo! Voices
Virtu Financial LLC Makes New Investment in Summit Therapeutics Inc. (NASDAQ:SMMT) - MarketBeat
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Wells Fargo Initiates Coverage of Summit Therapeutics (SMMT) with Overweight Recommendation - MSN
Summit Therapeutics (NASDAQ:SMMT) Earns Overweight Rating from Analysts at Wells Fargo & Company - MarketBeat
Summit Therapeutics (NASDAQ:SMMT) Earns Buy Rating from Analysts at Jefferies Financial Group - MarketBeat
Polar Asset Management Partners Inc. Takes Position in Summit Therapeutics Inc. (NASDAQ:SMMT) - MarketBeat
Why Summit Therapeutics Stock Rocketed 6% Higher on Friday - MSN
Bank of Montreal Can Invests $2.04 Million in Summit Therapeutics Inc. (NASDAQ:SMMT) - MarketBeat
The Manufacturers Life Insurance Company Raises Stock Holdings in Summit Therapeutics Inc. (NASDAQ:SMMT) - MarketBeat
Warning: This Skyrocketing Stock Has a Hidden Risk - AOL
Charles Schwab Investment Management Inc. Boosts Stake in Summit Therapeutics Inc. (NASDAQ:SMMT) - MarketBeat
Rakovina Therapeutics Announces Presentation at the 13th Annual Tumour Models London Summit - Yahoo Finance
Summit Therapeutics Inc. (NASDAQ:SMMT) Shares Acquired by Fmr LLC - MarketBeat
Summit Therapeutics Stock Set To Soar By Mid-2025 On HARMONi Phase 3 Trial - Seeking Alpha
Summit Therapeutics Inc. (NASDAQ:SMMT) Shares Acquired by Baker BROS. Advisors LP - MarketBeat
Billionaire Ken Griffin Is Selling Palantir and Buying a Stock Wall Street Expects to Rocket 139% Higher - Yahoo Finance
Cerity Partners LLC Invests $2.18 Million in Summit Therapeutics Inc. (NASDAQ:SMMT) - MarketBeat
2 Hot Biopharma Stocks to Buy and Hold for 5 Years - AOL
Intech Investment Management LLC Invests $694,000 in Summit Therapeutics Inc. (NASDAQ:SMMT) - MarketBeat
Stock Market Movers Today • Top Gainers & Losers - Benzinga
(SMMT) Investment Analysis and Advice - Stock Traders Daily
Summit Therapeutics to Present at Upcoming Investor Conferences - BioSpace
3 Monster Stocks in the Making - Yahoo Finance
Summit Therapeutics: Is Their Lung Cancer Drug a Game Changer? - MSN
Summit Therapeutics (SMMT) Hurt Bronte Capital. Here’s Why - Insider Monkey
Summit Therapeutics (NASDAQ:SMMT) Earns "Buy" Rating from HC Wainwright - MarketBeat
(SMMT) Trading Report - Stock Traders Daily
Merck Spends Up To $3.3 Billion In An Insurance Policy Against Summit Therapeutics - Investor's Business Daily
Merck signs up to $3.3 billion cancer drug deal with China-based LaNova - Reuters
Summit Therapeutics Inc Stock (SMMT) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.45%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):